¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ) : 2019-10-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ) : 2019-10-20
±³À°ÀÏÀÚ : 2019-10-20
±³À°Àå¼Ò : ¿öÄ¿Èú È£ÅÚ Art Ȧ ¿Ü  
±³À°ÁÖÁ¦ : KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ)
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258  
À̸ÞÀÏ : herz8@circulation.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡   (ÀÏ¹Ý 5Á¡ / Çʼö 1Á¡)  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 0¿ø      
ºñ°í »çÀüµî·Ï: ±³¼ö ¹× °³¿øÀÇ-100000, ÀüÀÓÀÇ/Àü°øÀÇ/±âŸ-70000ÇöÀåµî·Ï: ±³¼ö ¹× °³¿øÀÇ-120000, ÀüÀÓÀÇ/Àü°øÀÇ/±âŸ-90000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-20 Art 08:40~08:55 Pulmonary Hypertension with Significant Left to Right Shunt: How to Treat  ¹éÀç¼÷(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-20 Art 08:55~09:10 Treatment of Eisenmenger Syndrome in Adult  Àå¼ÒÀÍ(¼¼Á¾º´¿ø) 
±³À°½Ã°£ 10-20 Art 09:10~09:25 Pulmonary Thromboembolism in ACHD  ¹ÚÁ¤¶û(°æ»óÀÇ´ë) 
±³À°½Ã°£ 10-20 Art 09:25~09:40 Combined Pre- and Post-capillary Pulmonary Hypertension in ACHD  ±èÇü°ü(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-20 Art 09:40~09:55 Differential Diagnosis of Pulmonary Hypertension in ADHD: Multiple Comorbidity Condition  À强¾Æ(¼º±Õ°üÀÇ´ë) 
Åä·Ð 10-20 Art 09:55~10:10 Discussion  () 
È޽Ġ10-20  10:10~10:20 Break  () 
±³À°½Ã°£ 10-20 Theatre 10:20~10:40 The Past, Present and Future of HF Medical Treatment  Barry Greenberg(Univ. of California San Diego USA) 
±³À°½Ã°£ 10-20 Theatre 10:40~11:00 The Past, Present and Future of CRT  Eugene S. Chung(The Christ Hospital Cincinnati OH USA) 
±³À°½Ã°£ 10-20 Theatre 11:00~11:20 The Past, Present and Future of Heart Transplantation  Jon A. Kobashigawa(Cedars-Sinai USA) 
Åä·Ð 10-20 Theatre 11:20~11:50 Discussion  () 
È޽Ġ10-20  11:50~12:00 Break  () 
±³À°½Ã°£ 10-20 Cosmos 12:00~12:20 Combination Therapy of Antihypertensive Drugs for CV Protection Amosartan Family  ¼ÕÀϼ®(°æÈñÀÇ´ë) 
±³À°½Ã°£ 10-20 Cosmos 12:20~12:40 The Benefits of Intensive Lipid Lowering  ÃÖ¼ºÈÆ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 10-20 Abstract/Case zone & Moderated Poster zone 12:40~14:00 Case Presentation & Moderated Poster  ´Ù°­»ç(´Ù¼Ò¼Ó) 
±³À°½Ã°£ 10-20 Theatre 14:00~14:25 ÃֽŠ»ç·Ê¸¦ ÅëÇØ º» ÀÇ·á±â°ü-Á¦¾àȸ»ç/±â±âȸ»ç À±¸® Áöħ - ûŹ±ÝÁö¹ý ½ÃÇà ÀÌÈÄ  Á¶°Ç¹Ì(¼­¿ï¾Æ»êº´¿ø ¹ý¹«ÆÀ) 
Åä·Ð 10-20 Theatre 14:25~14:30 Discussion  () 
±³À°½Ã°£ 10-20 Theatre 14:30~14:55 º¯È­ÇÏ´Â ¿¬±¸ÃâÆÇÀ±¸®  Çѵ¿¼ö(ÇѾçÀÇ´ë ÀÇÇÐÇмúÁöÆíÁýÀÎÇùÀÇȸ ÃâÆÇÀ±¸®À§¿øÀå) 
Åä·Ð 10-20 Theatre 14:55~15:00 Discussion  () 
±³À°½Ã°£ 10-20 Theatre 15:00~15:25 ÀÇ»çÀ±¸®ÁöħÀÇ ¹ýÀûÇؼ®  ¹ÚÇü¿í(´Ü±¹ÀÇ´ë) 
Åä·Ð 10-20 Theatre 15:25~15:30 Discussion  () 
È޽Ġ10-20  15:30~15:40 Break  () 
±³À°½Ã°£ 10-20 Walker 2 15:40~16:00 How to Select Optimal NOAC in AF Patients Undergoing PCI? - Rivaroxaban vs. Dabigatran vs. Apixaban  ¹èÀåȯ(ÃæºÏÀÇ´ë) 
±³À°½Ã°£ 10-20 Walker 2 16:00~16:20 How to Manage Blood Thinners during Procedure or Surgery? - Antiplatelet or Anticoagulant for Primary and Secondary Prevention  ¾È¼º±Õ(¿¬¼¼¿øÁÖÀÇ´ë) 
±³À°½Ã°£ 10-20 Walker 2 16:20~16:40 How to Choose Optimal Blood Thinner after Structural Cardiovascular Intervention?  ¹Ú´ö¿ì(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-20 Walker 2 16:40~17:00 How to Adjust Blood Thinners in Patients with Old Age or CKD? - Dose or Regimen Adjustment According to CrCl vs. GFR  ±è¿ø(°æÈñÀÇ´ë) 
Åä·Ð 10-20 Walker 2 17:00~17:10 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ) : 2019-10-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦5Â÷ ÇÏÁöÁ¤¸Æ·ù¿¬±¸È¸ Çмú½ÉÆ÷Áö¿ò : 2019-10-20
´ÙÀ½±Û ¼­¿ï°­³²¼º¸ðº´¿ø Á¦46ȸ 2019³â ´ëÇÑÀϹݰúÀÇ»çȸ Ãß°è ¿¬¼ö°­Á : 2019-10-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20775 ¼­¿ï 2024³â °áÇÙ°ü¸®±³À° 1±â(1ÀÏÂ÷) : 2024-06-13 0 0 2024-05-27
20774 ºÎ»ê (¿Â¶óÀÎ) ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ ºÎ»ê¡¤¿ï»ê¡¤°æ³² ÁöºÎȸ 2024³â 06¿ù Çмú´ëȸ : 2024-06-13 0 0 2024-05-27
20773 ´ëÀü 2024 Á¦40ȸ ´ëÇѼҾƿܰúÇÐȸ Ãá°èÇмú´ëȸ ¹× 40Áֳ⠱â³äÇà»ç(1ÀÏÂ÷) : 2024-06-13 0 1 2024-05-27
20772 ´ë±¸ 2024 Á¦2Â÷ ´ëÇѺñ´¢ÀÇÇÐȸ ´ë±¸°æºÏÁöºÎÇÐȸ : 2024-06-13 0 2 2024-05-27
20771 ¼­¿ï ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2024³â Á¦19Â÷ Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-13 0 3 2024-05-27
20770 ¼­¿ï 2024 ´ëÇÑÈ­»óÇÐȸ Çмú´ëȸ(1ÀÏÂ÷) : 2024-06-13 0 2 2024-05-27
20769 ¼­¿ï 2024³â ±Ýõ±¸ÀÇ»çȸ 1Â÷ ¿¬¼ö±³À°(¿ì¿ïÁõ ¾àÁ¦, ÇǺÎÁúȯ, CBC¿Í LFT, À§¿°) : 2024-06-12 0 0 2024-05-27
20768 ¼­¿ï 2024 Á¦3ȸ ÀÌ°ÇÈñ ¼Ò¾Æ¾Ï¡¤Èñ±ÍÁúȯ ±Øº¹»ç¾÷ ¿¬±¸ÀÚ SKILL-UP Workshop : 2024-06-12 0 0 2024-05-27
20767 °æ±â ´ëÇÑÇǺΰúÇÐȸ Á¦78Â÷ °æ±âÁöºÎȸ ÇмúÁý´ãȸ : 2024-06-11 0 0 2024-05-27
20766 ±¤ÁÖ Á¦180Â÷ ´ëÇѼҾÆû¼Ò³â°úÇÐȸ ±¤ÁÖ¡¤Àü³²Áöȸ ÇмúÁý´ãȸ : 2024-06-11 0 2 2024-05-27
20765 ºÎ»ê ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ºÎ»ê,¿ï»ê,°æ³²Áöȸ - Á¦362Â÷ ¿ù·ÊÇмúȸ : 2024-06-11 0 9 2024-05-27
20764 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-06-11 0 5 2024-05-27
20763 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ(ÀÇ»ç) ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À° : 2024-06-11 0 5 2024-05-27
20762 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾÆÀÀ±ÞÀÇÇÐȸ Á¦ 32ȸ Á¤±â Áý´ãȸ : 2024-06-10 0 5 2024-05-27
20761 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø Á¦16ȸ KOALA Symposium 2024 : 2024-06-09 0 1 2024-05-27
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷